HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Cash from Financing Activities (2018 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly Cash from Financing Activities came in at $605.1 million in Q2 2021, up 4315.1% year-over-year from $13.7 million in Q2 2020, and up 2362.23% quarter-over-quarter from -$26.7 million in Q1 2021.

Analysis

HUTCHMED (China) (HMDCF) Cash from Financing Activities (2018 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Cash from Financing Activities for 4 consecutive years, with $605.1 million the latest figure, recorded in Q2 2021.

  • On a quarterly basis, Cash from Financing Activities rose 4315.1% year-over-year to $605.1 million in Q2 2021; TTM through Jun 2021 was $674.7 million, a 442.5% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, up 125.55% from the prior year.
  • Cash from Financing Activities was $605.1 million for Q2 2021 at HUTCHMED (China), up from -$26.7 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $605.1 million in Q2 2021 and troughed at -$29.2 million in Q2 2019.
  • A 4-year average of $56.8 million and a median of -$161000.0 in 2018 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities tumbled 1017.16% in 2019 and soared 32093.64% in 2020, its largest moves.
  • Over 4 years, Cash from Financing Activities stood at $16.0 million in 2018, then surged by 67.63% to $26.9 million in 2019, then tumbled by 153.36% to -$14.4 million in 2020, then surged by 4315.1% to $605.1 million in 2021.
  • The last three Cash from Financing Activities figures came in at $605.1 million (Q2 2021), -$26.7 million (Q1 2021), and -$14.4 million (Q2 2020), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 211.88 Bn 197.89 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 181.55 Bn 178.37 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 132.31 Bn 124.45 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 61.54 Bn 56.36 Bn 1.37 Bn -
6 Moderna 54.69 Bn 49.55 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 34.07 Bn 30.76 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.41 Bn 30.12 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn -181.51 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 605.08 Mn
Mar 31, 2021 -26.75 Mn
Jun 30, 2020 -14.36 Mn
Mar 31, 2020 110.70 Mn
Dec 31, 2019 26.90 Mn
Sep 30, 2019 1.12 Mn
Jun 30, 2019 -29.17 Mn
Mar 31, 2019 -346,000.00
Dec 31, 2018 16.05 Mn
Sep 30, 2018 24,000.00
Jun 30, 2018 -2.61 Mn
Mar 31, 2018 -5.23 Mn